Oxycodone

FDA Shifts Focus to Abuse-Deterrent Generic Opioid Development

FDA Shifts Focus to Abuse-Deterrent Generic Opioid Development

By Zachary Brennan

The US Food and Drug Administration (FDA) can require opioid generics to have abuse-deterrent properties if the same requirements are applicable to their brand name counterparts, FDA Commissioner Margaret Hamburg said in a letter to Rep. Fred Upton (R-Mich.)...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers